JP2023554081A5 - - Google Patents
Info
- Publication number
- JP2023554081A5 JP2023554081A5 JP2023537034A JP2023537034A JP2023554081A5 JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5 JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- variable region
- chain variable
- nucleotide sequence
- sequence seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011485792.8A CN114634575B (zh) | 2020-12-16 | 2020-12-16 | 一种补体抑制剂的开发和应用 |
| CN202011485792.8 | 2020-12-16 | ||
| PCT/CN2021/138447 WO2022127834A1 (zh) | 2020-12-16 | 2021-12-15 | 一种补体抑制剂的开发和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554081A JP2023554081A (ja) | 2023-12-26 |
| JP2023554081A5 true JP2023554081A5 (enExample) | 2024-04-15 |
Family
ID=81944764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537034A Pending JP2023554081A (ja) | 2020-12-16 | 2021-12-15 | 補体抑制剤の開発及び応用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067751A1 (enExample) |
| EP (1) | EP4265641A1 (enExample) |
| JP (1) | JP2023554081A (enExample) |
| KR (1) | KR20230118941A (enExample) |
| CN (4) | CN120173119B (enExample) |
| AU (1) | AU2021398697A1 (enExample) |
| CA (1) | CA3202507A1 (enExample) |
| IL (1) | IL303794A (enExample) |
| WO (1) | WO2022127834A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4353749A4 (en) * | 2021-06-08 | 2025-07-16 | Shanghai Jemincare Pharmaceuticals Co Ltd | ANTI-MASP-2 ANTIBODY AND ITS USE |
| JP2024524440A (ja) * | 2021-06-30 | 2024-07-05 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規抗ｍａｓｐ－２抗体 |
| WO2023103789A1 (zh) * | 2021-12-10 | 2023-06-15 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| EP4643878A2 (en) * | 2022-12-29 | 2025-11-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Pharmaceutical preparation comprising therapeutic antibody and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP2386315A1 (en) * | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2011265532B2 (en) * | 2004-06-10 | 2014-04-24 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2010306581B2 (en) * | 2009-10-16 | 2015-03-19 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
| CN107638565B (zh) * | 2011-04-08 | 2021-12-21 | 莱斯特大学 | 用于治疗与masp-2依赖性补体活化相关的状况的方法 |
| MX361175B (es) * | 2011-05-04 | 2018-11-29 | Omeros Corp | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
| AU2013201779B2 (en) * | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| SG11201805695SA (en) * | 2016-01-05 | 2018-07-30 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| CN109311988A (zh) * | 2016-07-06 | 2019-02-05 | 上海开拓者生物医药有限公司 | 一种BlyS抗体及其制备方法和应用 |
| JP2021527698A (ja) * | 2018-06-22 | 2021-10-14 | オメロス コーポレーション | 様々な血栓性の疾患および障害の治療のためのｍａｓｐ−２を阻害する組成物および方法 |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
-
2020
- 2020-12-16 CN CN202510392268.2A patent/CN120173119B/zh active Active
- 2020-12-16 CN CN202011485792.8A patent/CN114634575B/zh active Active
- 2020-12-16 CN CN202510392209.5A patent/CN120173118B/zh active Active
-
2021
- 2021-12-15 US US18/267,680 patent/US20240067751A1/en active Pending
- 2021-12-15 AU AU2021398697A patent/AU2021398697A1/en active Pending
- 2021-12-15 KR KR1020237023581A patent/KR20230118941A/ko not_active Withdrawn
- 2021-12-15 WO PCT/CN2021/138447 patent/WO2022127834A1/zh not_active Ceased
- 2021-12-15 IL IL303794A patent/IL303794A/en unknown
- 2021-12-15 CN CN202180085328.6A patent/CN116648464A/zh active Pending
- 2021-12-15 EP EP21905760.1A patent/EP4265641A1/en not_active Withdrawn
- 2021-12-15 CA CA3202507A patent/CA3202507A1/en active Pending
- 2021-12-15 JP JP2023537034A patent/JP2023554081A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL303794A (en) | Development and application of an inhibitory complement | |
| CN106211782B (zh) | 抗体-fynomer缀合物 | |
| JP2023509196A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| JP2019503167A5 (enExample) | ||
| US20250304717A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| JP2018527908A5 (enExample) | ||
| JP2006505277A5 (enExample) | ||
| JP2019522050A5 (enExample) | ||
| JP2021500391A5 (enExample) | ||
| JP2020511936A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2011505146A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP2012070737A5 (enExample) | ||
| AU2010248365A1 (en) | Anti-AXL antibody | |
| JP2023543493A5 (enExample) | ||
| JP2011518857A5 (enExample) | ||
| JP2022521850A5 (enExample) | ||
| CA3214808A1 (en) | Thienopyrrole compounds | |
| JP2008542321A5 (enExample) | ||
| JP2026048732A5 (enExample) | ||
| JP2011505371A5 (enExample) | ||
| JP2024512260A5 (enExample) |